RAPT Therapeutics (RAPT) Competitor Comparison
We are evaluating the key criteria listed to compare RAPT Therapeutics (RAPT) against its competitors in the Biotechnology industry.
Market Capitalization
197 / 368Gross Profits
120 / 278Total Revenue
299 / 300EBITDA
223 / 337Free Cashflow
217 / 352Quick Ratio
101 / 357Earnings per Share
264 / 359Dividend yield
0 / 6Total Cash
166 / 358Performance 3 years
314 / 368Performance 5 years
271 / 368Performance 10 years
197 / 368Linearity 3 years
196 / 368Linearity 5 years
130 / 368Linearity 10 years
57 / 368Total Rank
351 / 368Dividend Rank
255 / 368Valuation Rank
291 / 368Piotroski Rank
306 / 368Muliplier Rank
188 / 368EBITDA - RAPT ranking 223 / 337
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.